ARTICLE | Company News
Editas, Allergan deal
March 17, 2017 1:02 PM UTC
Editas granted Allergan an exclusive option to license up to five of Editas' CRISPR ocular programs. The deal includes Editas' lead candidate, which is in preclinical development to treat Leber's cong...